Abstract: A composition for preventing or treating hearing loss, containing a Vitis vinifera leaf extract as an active ingredient, is disclosed. A pharmaceutical composition for preventing or treating hearing loss, containing the extract (a Vitis vinifera leaf extract) as an active ingredient, protects auditory hair cells in the cochlea and spiral ganglion cells from damage caused by noise and the like and effectively reduces the hearing threshold measured in the auditory nerves, thereby being usable as an agent for preventing or treating hearing loss.

Abstract: The present invention relates to a combination formulation containing metformin for treating non-insulin-dependent diabetes and an HMG-CoA reductase inhibitor for treating dyslipidemia. The present invention provides a combination formulation and a method for preparing the combination formulation, wherein the combination formulation contains metformin and an HMG-CoA reductase inhibitor.

Abstract: Provided is a method of preventing and treating a dry eye syndrome comprising administering a pharmaceutical composition comprising sulglycotide or its pharmaceutically acceptable salt as an active ingredient.

Abstract: An electronic device is provided. The electronic device includes a power receiver (PRx) that includes a receiver coil for receiving a power signal from a wireless power transmitting device and a wireless charging integrated circuit (IC) for converting the power signal into electrical energy, a power management circuit that is electrically connected to the PRx and configured to charge a battery using the electrical energy, and a processor that is electrically connected with the PRx and the power management circuit. The processor activates a power hold mode (PHM) if a charging level of the battery is a fully charged level and controls auxiliary charging of the battery.

Abstract: Provided is a composition for preventing and treating a menopausal disorder containing extracts of Dendropanax morbifera LEV. as an active ingredient. Specifically, the extracts of Dendropanax morbifera LEV. exhibit a significant ER agonist activity within a cell, and exhibit a very potent ER agonist (full agonist) activity with an EC50 value of about 100 ?g/ml. Thus, the extracts of Dendropanax morbifera LEV. comprising a high content of plant metabolites similar to estrogen can be useful as hormone replacement therapy capable of improving various symptoms derived from a deficiency of estrogen in menopausal women.

Abstract: The present invention relates to a pharmaceutical composition, containing sarpogrelate or a pharmaceutically acceptable salt thereof as an active ingredient, for preventing, alleviating, or treating sensorineural hearing loss. The sarporgrelate according to the present invention protects against hearing loss caused by noise through the suppression of auditory cell apoptosis and the expression increase of antioxidant enzyme in auditory cells, and thus can be advantageously used in the prevention and alleviation of sensorineural hearing loss.

Abstract: An electronic device is provided. The electronic device includes a power receiver (PRx) that includes a receiver coil for receiving a power signal from a wireless power transmitting device and a wireless charging integrated circuit (IC) for converting the power signal into electrical energy, a power management circuit that is electrically connected to the PRx and configured to charge a battery using the electrical energy, and a processor that is electrically connected with the PRx and the power management circuit. The processor activates a power hold mode (PHM) if a charging level of the battery is a fully charged level and controls auxiliary charging of the battery.

Abstract: A surveillance server connected to a camera through a network is provided, the camera acquiring an image of a surveillance area. The surveillance server includes: a data acquisition unit configured to acquire from the camera image data of the image that is encrypted; a mode selection unit configured to select a processing mode of the image data; and a decryption control unit configured to decrypt the image data in response to selection of a first mode.

Abstract: The present invention relates to a pharmaceutical composition comprising dutasteride and propylene glycol monolaurate, which improves the stability of dutasteride, which is a poorly soluble drug as a 5-alpha reductase inhibitor, and a process for its preparation. More particularly, the present invention also relates to a capsule formulation which is smaller in size than a commercial dutasteride capsule formulation (AVODART®), but has the equivalent dissolution rate by preparing a pharmaceutical composition comprising propylene glycol monolaurate and dutasteride, which can improve the stability of the dutasteride. A dutasteride formulation having enhanced patient's compliance and improved stability and a method for producing the same are provided.

Abstract: The present disclosure relates to a pharmaceutical composition comprising dutasteride and propylene glycol monolaurate, and a capsule formulation comprising the same.

Abstract: Provided is a method of preventing and treating a dry eye syndrome comprising administering a pharmaceutical composition comprising sulglycotide or its pharmaceutically acceptable salt as an active ingredient.

Abstract: An electronic device is provided. The electronic device includes a power receiver (PRx) that includes a receiver coil for receiving a power signal from a wireless power transmitting device and a wireless charging integrated circuit (IC) for converting the power signal into electrical energy, a power management circuit that is electrically connected to the PRx and configured to charge a battery using the electrical energy, and a processor that is electrically connected with the PRx and the power management circuit. The processor activates a power hold mode (PHM) if a charging level of the battery is a fully charged level and controls auxiliary charging of the battery.

Abstract: The present invention relates to a capsule composite formulation comprising dutasteride represented by formula I, tadalafil represented by formula II, a fatty acid ester derivative having 8 to 10 carbon atoms, and a polysorbate- or polyoxylglyceride-based surfactant wherein both the two drugs are dissolved.

Abstract: A method of fabricating an integrated circuit (IC) includes depositing an aluminum-containing metal interconnect layer at a first temperature over a semiconductor device having a plurality of transistors. The metal interconnect layer is annealed at a maximum annealing temperature that is less than the first temperature. The metal interconnect layer is patterned after the annealing, thereby interconnecting the transistors.

Abstract: The present invention is related to a composite formulation of dutasteride and tadalafil, therapeutic agents for prostatic hyperplasia, and to an oral capsule preparation containing the same. The composite formulation has the total amount of the composition inside a capsule of 400 mg or less so that the size of the capsule is convenient for the patient to take so as to increase patients' convenience, and includes a glycerol fatty acid ester derivative or a propylene glycol fatty acid ester derivative which may increase the solubility of dutasteride, a poorly soluble medicament and improve the stability of tadalafil so as to dissolve dutasteride and disperse tadalafil.

Abstract: Provided are a semiconductor device and a method for fabricating the same. The semiconductor device includes an active fin protruding upwardly from a substrate and extending in a first direction and a gate structure extending in a second direction intersecting to cross the active fin, where a first width of a lower portion of the gate structure that contacts the active fin is greater than a second width of the lower portion of the gate structure that is spaced apart from the active fin.

Abstract: A method of fabricating an integrated circuit (IC) includes depositing an aluminum-containing metal interconnect layer at a first temperature over a semiconductor device having a plurality of transistors. The metal interconnect layer is annealed at a maximum annealing temperature that is less than the first temperature. The metal interconnect layer is patterned after the annealing, thereby interconnecting the transistors.

Abstract: The present disclosure relates to a pharmaceutical composition comprising dutasteride and propylene glycol monolaurate, and a capsule formulation comprising the same.

Abstract: The present invention relates to a continuous process for preparing microspheres and microspheres prepared thereby, and in particular, a process for preparing microspheres comprising steps of injecting a first emulsion and a second emulsion at the same time to form microspheres instantaneously, applying high pressure to the microspheres formed, and injecting the microspheres into an agitator, wherein the steps can be carried out continuously, and microspheres prepared thereby. When microspheres are prepared using the method of the present invention, scale variables, which have been the biggest disadvantage in existing preparation methods of microspheres, can be significantly reduced, drug encapsulation efficiency can be improved, and small and uniform particles can be obtained.

Abstract: Provided are a semiconductor device and a method for fabricating the same. The semiconductor device includes an active fin protruding upwardly from a substrate and extending in a first direction and a gate structure extending in a second direction intersecting to cross the active fin, where a first width of a lower portion of the gate structure that contacts the active fin is greater than a second width of the lower portion of the gate structure that is spaced apart from the active fin.